Human endothelial cells (HECs) in confluent primary culture reproduce the epithelioid organization of the vascular lining in situ. The addition of greater than or equal to 20 U/ml recombinant tumor necrosis factor (rTNF) or greater than or equal to 16 U/ml recombinant immune interferon (rIFN-gamma) causes HECs 1) to become elongated, 2) to overlap, 3) to rearrange their actin filaments, and 4) to lose their stainable fibronectin matrix. These changes develop over 72-96 hours and are reversible upon withdrawal of the mediator. In serially passaged HECs similar morphologic changes develop. Furthermore, rTNF and rIFN-gamma are each cytostatic for subconfluent passaged cultures. When added in combination, low concentrations of rTNF and rIFN-gamma act synergistically, whereas higher concentrations (eg, 100 U/ml rTNF and 200 U/ml rIFN-gamma) produce unique morphologic changes. Doubly treated primary HECs extend many long, overlapping, spinelike processes and expose the substratum. Doubly treated passaged HECs become extremely elongated and then shed in large numbers. These in vitro changes in endothelial cell morphology and behavior may underlie immunologically mediated vascular responses in vivo.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1888144PMC

Publication Analysis

Top Keywords

recombinant tumor
8
tumor necrosis
8
necrosis factor
8
immune interferon
8
endothelial cell
8
greater equal
8
equal u/ml
8
u/ml recombinant
8
changes develop
8
passaged hecs
8

Similar Publications

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.

ESMO Open

January 2025

Uro-Gynecologic Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Electronic address:

Background: Ovarian cancer (OvC) constitutes significant management challenges primarily due to its late-stage diagnosis and the development of resistance to chemotherapy. The standard treatment regimen typically includes carboplatin and paclitaxel, with the addition of poly (ADP-ribose) polymerase inhibitors for patients with high-grade serous ovarian cancer (HGSOC) harboring BRCA1/2 mutations. However, the variability in treatment responses suggests the need to investigate factors beyond BRCA1/2 mutations, such as DNA repair mechanisms and epigenetic alterations.

View Article and Find Full Text PDF

Translationally controlled tumor protein (TCTP) is a well conserved and ubiquitously expressed multifunctional protein found in many organisms and is involved in many pathophysiological processes like cell proliferation, differentiation, development and cell death. The role of TCTP in anti-apoptosis and cancer metastasis makes it a promising candidate for cancer therapy. Dictyostelium discoideum, a protist, has two isoforms (TCTP1 and TCTP2, now referred to as TPT1 and TPT2) of which we have earlier elucidated TPT1.

View Article and Find Full Text PDF

Objective: Interleukin-17 E (IL-17E) is a pro-inflammatory cytokine that participates in the inflammatory response and tumorigenesis. However, the function of IL-17E in non-small cell lung cancer (NSCLC) remains largely unknown.

Methods: The clinical value of IL-17E was determined by immunohistochemistry (IHC) in 75 cases of NSCLC tissues.

View Article and Find Full Text PDF

Most of advanced non-small cell lung cancer (NSCLC) patients will experience tumor progression with immunotherapy (IO). Preliminary data suggested an association between high plasma HGF levels and poor response to IO in advanced NSCLC. Our study aimed to evaluate further the role of the HGF/MET pathway in resistance to IO in advanced NSCLC.

View Article and Find Full Text PDF

Background: Diabetes is a modifiable risk factor for Alzheimer's disease, and GLUT4, an insulin-dependent transporter, plays a crucial role in insulin-resistant conditions and, consequently, in diabetes development. The study aimed to investigate the relationship between tau pathology and insulin resistance by quantifying GLUT4 expression and glucose concentration.

Method: Initially, SH-SY5Y cells underwent transfection with either a wild-type tau plasmid or a mutant tau plasmid.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!